Exciting News from Boundless Bio
San Diego-based Boundless Bio is making headlines in the world of oncology with their innovative research and upcoming participation at a significant conference focused on cancer therapeutics. This announcement coincides with their commitment to address the challenging nature of oncogene amplified tumors, a prevalent issue affecting many cancer patients today.
Details About the Upcoming Conference Presentation
Boundless Bio, recognized for its groundbreaking work, is set to present their findings at the AACR-NCI-EORTC International Conference specializing in Molecular Targets and Cancer Therapeutics. The conference is scheduled from October 22 to October 26, known for showcasing cutting-edge research and advancements in cancer treatment. This presentation will provide a platform for them to discuss their innovative approach to combating oncogene amplified cancers.
Presentation Highlights
The centerpiece of Boundless Bio's conference participation will be a poster presentation titled, 'Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355 targets unique dependencies of oncogene amplified cancers.' Scheduled on October 23 from 12:30 to 4:00 PM ET, the session promises to delve into the unique aspects of their research, particularly the interaction of these inhibitors in the fight against cancer.
Understanding the Research Focus
At the heart of Boundless Bio's research lies the study of extrachromosomal DNA (ecDNA), a piece of genomic material linked to oncogene amplification. Approximately 14% to 17% of cancer patients exhibit this challenging condition, which can complicate treatment options. Through their work, Boundless Bio aims to provide new hope for patients who have faced limited treatment options.
Innovative Therapies Under Development
Boundless Bio is at the forefront of developing pioneering treatments targeted specifically at the mechanisms that contribute to oncogene amplification. Among their key therapeutic candidates are BBI-355, a selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, which targets ribonucleotide reductase (RNR). These compounds are currently undergoing evaluation in combination within their phase 1/2 POTENTIATE clinical trial, aimed at providing comprehensive solutions for patients.
The Future of ecDNA-Directed Therapeutics
In addition, Boundless Bio is progressing toward introducing an additional ecDNA-directed therapeutic candidate, BBI-940. This innovative compound is expected to be a first-in-class, selectively degrading Kinesin, representing a potentially significant advancement in cancer therapeutics. The ongoing IND-enabling studies are set to pave the way for further development and patient access to this promising treatment.
Commitment to Patients and Innovation
With a strong commitment to unraveling the complexities of cancer treatment, Boundless Bio continues to address persistent needs within therapeutic modalities. Their determination to develop ecDNA-targeted treatments symbolizes a transformative shift towards personalized cancer therapies designed for those with oncogene amplified tumors. Headquartered in San Diego, they are combining advanced research with compassionate patient care.
Engagement and Communication
For more information about Boundless Bio and their innovative work, they encourage interested parties to visit their website and connect through various platforms. Active engagement with the community is a top priority for the company, reflecting their openness to inquiries and collaboration.
Frequently Asked Questions
What is the focus of Boundless Bio's research?
Boundless Bio primarily focuses on developing therapies targeting oncogene amplified tumor cells through their novel exploration of extrachromosomal DNA.
When is the upcoming conference presentation?
The conference presentation is scheduled for October 23 at the AACR-NCI-EORTC International Conference, from 12:30 to 4:00 PM ET.
What innovative therapies are being developed by Boundless Bio?
They are developing several ecDNA-directed therapeutic candidates, including BBI-355 and BBI-825, aimed at combating oncogene amplified cancers.
What is ecDNA and why is it important?
Extrachromosomal DNA (ecDNA) is linked to oncogene amplification, which complicates cancer treatment and is a critical focus of Boundless Bio's research initiatives.
How can I learn more about Boundless Bio?
You can visit their website for more information or follow them on social media platforms to stay updated on their latest research and developments.
